Long-term outcome and prognostic factors of second allogeneic hematopoietic stem cell transplant for acute leukemia in patients with a median follow-up of ≥10 years

G. Andreola, M. Labopin, D. Beelen, P. Chevallier, R. Tabrizi, A. Bosi, M. Michallet, S. Santarone, G. Ehninger, E. Polge, D. Laszlo, C. Schmid, A. Nagler, M. Mohty

Research output: Contribution to journalArticle

Abstract

Second allogeneic hematopoietic stem cell transplantation (HSCT2) is a frequently used treatment option for relapse of acute leukemia after first allogeneic transplantation. Remission can be induced in selected patients, but data on long-term outcome and finally cure are limited. To estimate the long-term results of HSCT2, we retrospectively analyzed the course of 286 patients receiving myeloablative HSCT2 between 1985 and 2000, with a median follow-up of 11.3 years. Overall survival (OS) and leukemia-free survival (LFS) at 10 years from HSCT2 were 10±2 and 7±2%, respectively. Cumulative 10-year incidence of relapse and non-relapse mortality were 58±3% and 35±3%, respectively. CR at HSCT2, an interval from first transplant to relapse >10 months and TBI as part of the conditioning for HSCT2 favorably influenced LFS and OS. Patients with all three favorable factors had a 10-year OS of 36±10% and LFS of 25±9%, whereas patients showing no favorable factor had all died before year 5. Although retrospective, the long follow-up of this analysis supports the curative potential of alloHSCT2 in selected patients, who might be identified in advance, based on prognostic factors.

Original languageEnglish
Pages (from-to)1508-1512
Number of pages5
JournalBone Marrow Transplantation
Volume50
Issue number12
DOIs
Publication statusPublished - Dec 1 2015

    Fingerprint

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Andreola, G., Labopin, M., Beelen, D., Chevallier, P., Tabrizi, R., Bosi, A., Michallet, M., Santarone, S., Ehninger, G., Polge, E., Laszlo, D., Schmid, C., Nagler, A., & Mohty, M. (2015). Long-term outcome and prognostic factors of second allogeneic hematopoietic stem cell transplant for acute leukemia in patients with a median follow-up of ≥10 years. Bone Marrow Transplantation, 50(12), 1508-1512. https://doi.org/10.1038/bmt.2015.193